Chimeric TherapeuticsCHMMF -96.67%13 EPS without NRI is $-0.42 as of Dec. 2025. GuruFocus rates CHMMF with a GF Score™ of 13/100. The stock has 1 warning sign investors should review. Among 1,170 Biotechnology companies, Chimeric Therapeutics ranks better than 78.29% on this metric.
Chimeric Therapeutics's earnings per share without non-recurring items for the
six
months ended in Dec. 2025 was $-0.09.
Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.42.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
The historical rank and industry rank for Chimeric Therapeutics's EPS without NRI or its related term are showing as below:
CHMMF'
s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 38.4 Med: 40 Max: 41.6
Current: 41.6
CHMMF's 3-Year EPS without NRI Growth Rate is ranked better than 78.29% of 1170
companies
in the Biotechnology industry
Industry Median: 16.75
vs CHMMF: 41.60
Chimeric Therapeutics (OTCPK:CHMMF) EPS without NRI Explanation
EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Chimeric Therapeutics EPS without NRI Related Terms
Chimeric Therapeutics EPS without NRI Historical Data
* Premium members only.
The historical data trend for Chimeric Therapeutics's EPS without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHMMF vs VRTX, REGN, ALNY: EPS without NRI Comparison
For the Biotechnology subindustry, Chimeric Therapeutics's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chimeric Therapeutics PE Ratio without NRI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Chimeric Therapeutics's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where Chimeric Therapeutics's PE Ratio without NRI falls into.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.
EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.42
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chimeric Therapeutics (CHMMF) has a EPS without NRI of $-0.42 as of Dec. 2025. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Chimeric Therapeutics and its competitors. According to the industry distribution chart, Chimeric Therapeutics ranks #254 out of 1170 companies in the Biotechnology industry, placing it in the top 21.7%.
Is Chimeric Therapeutics' EPS without NRI too high?
Chimeric Therapeutics' current EPS without NRI is $-0.42. Based on the distribution chart, Chimeric Therapeutics ranks #254 out of 1170 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Chimeric Therapeutics has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Chimeric Therapeutics' EPS without NRI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Chimeric Therapeutics ranks #254 out of 1170 companies for EPS without NRI. This places Chimeric Therapeutics in the top 22% of its industry — outperforming the majority of peers. The industry median EPS without NRI is 16.75. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Biotechnology company?
The median EPS without NRI among Biotechnology companies is 16.75, based on 1,170 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Chimeric Therapeutics and its competitors. For the Biotechnology industry, the median EPS without NRI is 16.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chimeric Therapeutics's current EPS without NRI is $-0.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chimeric Therapeutics stock overvalued right now?
Chimeric Therapeutics (CHMMF) has a current EPS without NRI of $-0.42. The current EPS without NRI is $-0.42. Chimeric Therapeutics' overall GF Score™ is 13/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Chimeric Therapeutics (CHMMF), the current EPS without NRI is $-0.42 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Chimeric Therapeutics Ltd is an Australian clinical-stage cell therapy company focused on developing and commercialising a range of cell therapies in oncology. The group's products under development include T Cell Derived Autologous Therapies and Natural Killer (NK) Cell Derived Allogenic Therapies. T Cell Derived Autologous therapy works by engineering the T cells with the exact coordinates to attack and kill cancer. NK Cell Derived Allogenic Therapies from healthy donors can be manufactured on a large scale and, once administered, kill cancer. Its pipeline products include CDH17, CLTX, and CORE NK. The group has one reportable segment, being the research, development, and commercialisation of health technologies.
13GF Score
Get the complete analysis for CHMMF
EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHMMF has been successfully added to your 
